



**HAL**  
open science

## Epoxiconazole alters the histology and transcriptome of mouse liver in a transgenerational pattern

Ludovic Le Corre, Axelle Brulport, Daniel Vaiman, Marie-Christine Chagnon

### ► To cite this version:

Ludovic Le Corre, Axelle Brulport, Daniel Vaiman, Marie-Christine Chagnon. Epoxiconazole alters the histology and transcriptome of mouse liver in a transgenerational pattern. *Chemico-Biological Interactions*, 2022, 360, pp.109952. 10.1016/j.cbi.2022.109952 . hal-03690009

HAL Id: hal-03690009

<https://institut-agro-dijon.hal.science/hal-03690009>

Submitted on 22 Jul 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 Epoxiconazole alters the histology and transcriptome of mouse liver in a transgenerational  
2 pattern.

3 Ludovic LE CORRE<sup>1\*</sup>, Axelle BRULPORT<sup>1</sup>, Daniel VAIMAN<sup>2</sup>, Marie-Christine  
4 CHAGNON<sup>1</sup>.

5 <sup>1</sup> UMR1231, Institut Agro, INSERM, Université Bourgogne Franche-Comté, F-21000, Dijon,  
6 France

7 <sup>2</sup> Inserm U1016, CNRS UMR8104, Institut Cochin, équipe FGTB, F-75014 Paris, France

8

9

10 \* Corresponding author: Dr. LE CORRE Ludovic, PhD, NUTox laboratory, UMR U1231  
11 INSERM, AgroSup Dijon, 1 Esplanade Erasme, 21000 Dijon, France.

12 e-mail: ludovic.le-corre@agrosupdijon.fr

13 tel: (+33)380774035

14 fax: (+33)380774033

15

16

17

18

19

20

21

22

23

24 **Abstract**

25 Background: The use of phytosanitary products is always associated with their safety concern  
26 on the environment and on health. The associated adverse effects are very broad and  
27 substance-dependent. Among these substances, epoxiconazole (EPOX) is one of the most  
28 widely used fungicides, especially in beet crops. Although its use is questionable or even  
29 prohibited in the European Union, it is still widely used and its consequences  
30 (transgenerational effects) on future generations is unknown.

31 Objectives: We aimed to investigate the hepatic effects of epoxiconazole in the descendants of  
32 perinatally exposed low-dose C57Bl/6J mice, focusing on liver histological and  
33 transcriptomic analyses.

34 Methods: From day 0 of gestation up to day 21 postnatal, only pregnant F0 C57BL6/J mice  
35 were exposed to EPOX (1.75 µg/kg bw/day). F1 males and females were mated to obtain the  
36 F2 generation and similarly, F2 mice were crossed to obtain F3. Histological and  
37 transcriptomic analyses of the liver were performed. Gene set enrichment analysis was  
38 realized to determine an *a priori* defined set of genes with significantly altered mRNA  
39 expression. Plasma parameters were also measured.

40 Results and conclusions: Perinatal exposure to EPOX induces transgenerational effects with  
41 phenotypic, histological and transcriptomic changes in the liver. These changes are highly  
42 dependent on the sex and generation of the animal. All these modifications lead to an  
43 alteration of the hepatic metabolism resulting in a difference in the size of the hepatocytes.  
44 Beyond these specific mechanisms, EPOX also seems to have a more general impact on  
45 hepatic metabolism *via* the circadian rhythm.

46 Keywords: transgenerational effects, epoxiconazole, low dose and perinatal exposure,  
47 hepatotoxicity, Endocrine Disruptor

48

49 **1. Introduction**

50 Exposures to endocrine disrupting pesticides are likely to contribute substantially to  
51 diseases and physiological dysfunctions throughout life (Trasande et al., 2015). Adverse  
52 effects of endocrine disruptors affect exposed individuals, but can also alter the health of their  
53 descendants as well as subsequent generations even if they have not directly been exposed.  
54 Most of these so-called transgenerational effects are most often observed following perinatal  
55 exposure (Diamanti-Kandarakis et al., 2009; Gore, 2015). These responses often occur with a  
56 specific gender effect in the offspring due to the existence of different environmental  
57 adaptation mechanisms between males and females (Curley et al., 2011; Dunn et al., 2011;  
58 Sugathan and Waxman, 2013). They obviously depend on the nature, the window and the  
59 duration of the exposure, and the dose. Among the multitude of compounds used in  
60 agriculture, which are very controversial, epoxiconazole (EPOX) has been the subject of  
61 many criticisms for its potential effects on human health. EPOX ((2RS, 3SR) -1- [3- (2-  
62 chlorophenyl) -2,3-epoxy-2- (4-fluorophenyl) propyl] -1H-1,2,4-triazole, is an active  
63 substance of plant protection products belonging to the triazole class and used in the control  
64 of various fungal diseases in cereals, rice, sugar beets, bananas, coffee and soybeans. EPOX  
65 like all azole fungicides inhibits ergosterol demethylase (CYP51), an essential enzyme for  
66 fungal membrane synthesis, resulting in membrane disruption. The tolerable daily intake  
67 (TDI) defined by EFSA is 8 µg/kg bw/d (based on a two-generation reproduction study in the  
68 rat) and the acute reference dose (ARf) is 0.023 mg/kg bw in the same species. Regarding oral  
69 exposure, EFSA estimates it to be less than 17% of the TDI, with sugar beet root being the  
70 main contributor to the dietary exposure. For consumers, assessments of the theoretical  
71 maximum daily intake (MTDD) at international and national levels showed that chronic  
72 exposure is less than 20% (1.6 µg/kg bw/d) of the epoxiconazole TDI. Several studies have  
73 evaluated the harmful effects of EPOX in mammals, but almost all of the studies have been

74 carried out with very high doses (> 10 mg /kg bw /d) which is not representative of exposure  
75 levels in humans. These studies showed that EPOX could induce reprotoxic and hepatotoxic  
76 effects (with a potential development of hepatocarcinoma (DAR, 2006)). EPOX is a  
77 carcinogenic, mutagenic and reprotoxic (CMR) substance classified in substances C2 and  
78 R1B (European Regulation 1272/2008 modified by UE944/2013, annex II). EPOX also has  
79 endocrine disrupting activity as it has been described *in vitro* as a weak estrogenic compound  
80 and an anti-androgen (Vinggaard et al., 1999). EPOX is also able to inhibit the production of  
81 testosterone and estradiol in H295R cells (steroid synthesis test) (Wuttke et al., 2001). Indeed,  
82 EPOX is an inhibitor of CYP 450 enzyme, such as aromatase involved in the synthesis of  
83 estrogen and lanosterol 14 $\alpha$ -demethylase (or CYP51A1), responsible for an essential step in  
84 the biosynthesis of sterols and then of steroids (Lepesheva et al., 2008). However, high doses  
85 of EPOX appear to be hepatotoxic and impair body weight gain in rodent studies (Goetz et al.,  
86 2007). In addition, there are no studies regarding the biological effect of low dose EPOX  
87 and/or at environmental doses. Another important concern regarding endocrine disruptors is  
88 their potential effects in a generational or transgenerational model.

89 Here, we analyzed hepatotoxicity after perinatal exposure of the F1 generation to  
90 EPOX at 1.75  $\mu$ g/kg bw/day. We also investigated these disturbances on three generations  
91 (F1, F2 and F3) of male and female C57BL6 / J mice. Analyses were focused on the liver  
92 histology and transcriptome profile.

93

## 94 **2. Methods**

### 95 2.1. Animals and materials

96 Pregnant C57Bl/6J mice were provided by Charles Rivers. Epoxiconazole was  
97 purchased from Sigma-Aldrich CAS no. 133855-98-8. Diet (4RF21; Mucedola 4RF2) is  
98 certified as estrogen free (phytoestrogen concentration is lower than 4 ppb) and accurately

99 tested for the detection of estrogenic activities. Cholesterol FS™, Triglyceride FS™ and No  
100 Esterified Fatty Acids (NEFA) FS™ kits were obtained from DiaSys. Blood glucose test  
101 strips and glucometers (Accu-Check® Aviva, Roche Diagnostics) were provided from the  
102 pharmacy of the University (Dijon, France).

103

## 104 2.2. Experimental design

105 The mice had free access to food and water with a 12-hour light-dark cycle and a  
106 controlled room temperature of 22°C. Thirty-three F0 pregnant C57Bl/6J mice were  
107 individually housed. F0 Mice were exposed to epoxiconazole from the first day of gestation  
108 up to post-natal day 21 of F1 offspring

109 After mating, gestation day 0 (GD0) was determined in the morning by observation of  
110 the vaginal plug. Mice of the F0 generation (16 females) were exposed to GD0 epoxiconazole  
111 and exposure continued in F1 offspring until postnatal day 21 (JPN21). The epoxiconazole  
112 was resuspended in ethanol and diluted in drinking water to 8.5 ng/ml and the final ethanol  
113 concentration was 0.1%. The drinking water of the control group (17 females) contained only  
114 0.1% ethanol. The average weekly exposure to epoxiconazole was determined by measuring  
115 the mouse water consumption (equal to the difference in the weight of the water bottles over  
116 one week). Thus, the average epoxiconazole intake was 1.75 ( $\pm$  SD 0.14)  $\mu$ g/kg bw/d.

117 Ten week-old male and female mice were crossed to generate the mice of the F2 and  
118 F3 generations. The mated mice came from different litters. At weaning, a maximum of six  
119 mice were housed per cage, ensuring that the litters were mixed randomly after weaning to  
120 minimize a possible litter effect. Based on these conditions and for each generation, 12 male  
121 and female mice were analyzed.

122 At 23 weeks, 4h-fasting mice were euthanized. Before euthanasia, body weight, fat  
123 and lean masses were measured. Then, the mice were anesthetized with isoflurane, the blood

124 was taken by cardiac puncture and the mice were euthanized by cervical dislocation. The liver  
125 was drained of blood with physiological NaCl *via* the portal vein and weighed. A piece of the  
126 right lateral hepatic lobe was fixed in 4% paraformaldehyde and embedded in paraffin.  
127 Experimental protocol (Accreditation Number: #11422) was approved by the University of  
128 Burgundy's ethic committee and accredited by the ministry. Animal experiments have been  
129 carried out in accordance with EU Directive 2010/63/EU for animal experiments.

130

### 131 2.3. Body weight monitoring and corporal composition measurement

132 Mice were weighed weekly and before the euthanasia. Fat and lean masses were also  
133 measured individually using a quantitative EchoMRI 500T™ (EchoMRI, Houston, USA).  
134 Before each measurement, a calibration was performed according to the manufacturer's  
135 instructions.

### 136 2.4. Food intake measurement

137 Food was weighed daily for four consecutive days. Daily food intake was defined as  
138 the difference between the initial and remaining amounts of food after 24 h. Thus, the daily  
139 consumption was calculated from the average of the data obtained for three consecutive days.  
140 Particular attention was paid to spills and/or hoarding. Spilled food was weighed and  
141 subtracted from the measurements if necessary.

142

### 143 2.5. Biochemical analysis

144 Blood was collected by cardiac puncture during the euthanasia and centrifuged at  
145 2000g, 10 min and 4°C. The level of total plasma cholesterol, triglycerides, NEFA and insulin  
146 were measured using respective kits and according to the manufacturer's instructions. Blood  
147 glucose levels were determined from a tail blood sample collected before anaesthesia.

148

## 149 2.6. Histological analysis

150 Histology experiments were performed on the DimaCell platform (INSERM  
151 UMR1231, Dijon). As described above, a piece of the right lateral hepatic lobe was  
152 immediately fixed in 4% paraformaldehyde, then dehydrated and embedded in paraffin block.  
153 Fixed liver sections (5  $\mu$ m) were stained with hematoxylin-eosin or sirius red (hepatic fibrosis  
154 analysis). The sections were visualized by optical microscopy (in polarized light for sirius  
155 red) ( $\times$ 10 for sirius red staining; Zeiss Axioscope A1 with a Jenoptic Gryphax camera and  
156  $\times$ 40 for hematoxylin-eosin staining; Axiovert 25; Zeiss). Images were analyzed with ImageJ  
157 software. Four sections were performed for each mouse and three mice per group were  
158 analyzed. Kupffer cells were counted over the entire area of four different areas of each  
159 section. The hepatocyte size was measured on five clearly identifiable cells in four distinct  
160 areas of each section. The quantification of sirius red labeling was carried out using an  
161 algorithm (Visiolog software) on the entire surface of the section (excluding vascular  
162 elements). For this part, three sections were analyzed for each mouse and three mice per  
163 group were analyzed.

164 Transcriptomic analysis.

## 165 2.7 Transcriptomic analysis

166 A piece of the right lateral hepatic lobe was ground and homogenized (Sigma-Aldrich, Saint  
167 Quentin Fallavier, France) in a Precellys <sup>TM</sup> 24 tissue homogenizer (Bertin technologies,  
168 Montigny-le-Bretonneux, France) and using Tubes Lysing Matrix D <sup>TM</sup> (MP Biomedical,  
169 Illkirch-Graffenstaden, France). For total RNA extraction, the liver sample was ground in Tri-  
170 reagent <sup>TM</sup> and the classical phenol/chloroform method was performed. The quality of the  
171 RNAs (RNA Integrity Number) and their quantification were carried out by capillary  
172 electrophoresis (Agilent 2100 bioanalyzer, Les Ullis, France).



173 For the microarray assays, each sample consisted of a pool of RNA from the liver of  
174 three separate mice from different litters. The constitution of the pools was based on the  
175 quality of the nucleic acids in order to have three homogeneous samples. Equal amounts of  
176 nucleic acid were used for each mouse. A total of 200 ng (66 ng RNA per mouse) was  
177 required for microarray analysis. Thus, for each group (epoxiconazole and control), hepatic  
178 RNAs from nine mice (three pools of three mice per microarray assay) were analyzed. The  
179 composition of RNA pools was different as they depended on the respective nucleic acid  
180 quality.

## 181 2.8 Microarray and bioinformatics analysis

182 Cartridges of Affymetrix Clariom S array hybridization were used to analyze the global gene  
183 expression from isolated cRNA. The standard validated protocol were carried out at the  
184 Genomics Platform of the Cochin Institute. The genes showing a significant deregulation  
185 ( $p \leq 0.05$ ) were converted to ENSEMBL ID with Biomart and mm10 version of the mouse  
186 genome (<http://www.ensembl.org/biomart>). The .CEL type files were analyzed with the  
187 Transcription Analysis Console 4.0 (TAC 4.0; Affymetrix, Applied Biosystems). Differential  
188 expression in mRNA was shown as a pie chart and heat map. For downregulated or  
189 upregulated genes, a functional gene set enrichment analysis (GSEA) was performed with  
190 WebGestalt 2019 (WEB-based Gene Set AnaLysis Toolkit) (<http://www.webgestalt.org/>)  
191 using KEGG pathway database.

## 192 2.9 Statistical analysis

193 All data were expressed as mean  $\pm$  standard deviation (SD) and considered statistically  
194 significant different at  $p < 0.05$  using Student's unpaired t-test. Gaussian distributions and equal  
195 variances were previously verified with Graph Pad Prism® software. The Chi-square test was  
196 performed to determine the difference in hepatocyte size between each group ( $p < 0.05$ ).

197

### 198 **3. Results**

#### 199 3.1. Multigenerational effects of epoxiconazole on physiological and plasma parameters

200 ***Body weight and corporal composition*** (Table 1): Exposure to epoxiconazole did not  
201 induce any change in the body weight of the F1 and F2 mice regardless of sex. Only a  
202 significant decrease ( $p < 0.01$ ) in the weight of male F3 mice was observed (8% compared to  
203 the control group). No changes were found in the body composition (fat and lean mass) of  
204 these animals. In females, regards the body composition, only the fat mass of the F1 female  
205 mice decreased in the EPOX (9.3% SD  $\pm$  2.4;  $p < 0.01$ ) groups compared to the control group.

206 ***Food intake and water consumption*** (Table 1): In males, decreases in food intake and  
207 water consumption (normalized to body weight) were observed in F2 mice (5.3% compared to  
208 the control group;  $p < 0.01$ ) which were exacerbated in F3 mice (15.7% compared to the  
209 control group;  $p < 0.01$ ).

210 ***Serum lipids, glucose and insulin levels*** (Table 1): Whatever the sex and generation,  
211 no differences were found in glucose and insulin plasma levels. In male mice, only the total  
212 cholesterol plasma levels decreased in the F1 animals (30% compared to control group,  
213  $p < 0.01$ ). No differences were observed for triglycerides and NEFA (Non-Esterified Fatty  
214 Acids) plasma levels. In males of the F2 and F3 generation, there was no difference in these  
215 blood parameters.

216 Female F1 mice exposed to epoxiconazole exhibited higher total cholesterol and  
217 triglyceride plasma levels respectively 40 and 70% than in the control group. In females of the  
218 F2 generation, effect on total cholesterol plasma level disappeared, but it persisted for  
219 triglycerides with a 30% increase in the EPOX group compared to the control group. On the  
220 other hand, an induction (170%) of the plasma level of NEFA was observed. No more  
221 changes were observed in the F3 generation.

222

223 Table 1: Transgenerational study of epoxiconazole effects on physiological and plasma

224 parameters in male (upper table) and female (lower table) mice.

	F1 male		F2 male		F3 male	
	CTRL	EPOX	CTRL	EPOX	CTRL	EPOX
Body Weight (g)	28.7 ± 2.1	28.6 ± 1.7	31.1 ± 2.84	30.4 ± 2.2	32.1 ± 1.87	<b>29.5 ± 1.76</b>
Fat mass (%)	10.7 ± 1.7	10.8 ± 1.1	13.7 ± 4.4	12.4 ± 2.4	13.6 ± 1.9	12.8 ± 3.0
Lean Mass (%)	76.9 ± 1.9	76.9 ± 2.2	74.1 ± 5.6	74.6 ± 3.6	74.4 ± 1.6	74.9 ± 3.2
Liver Weight (g)	1.21 ± 0.14	1.19 ± 0.15	1.32 ± 0.13	1.25 ± 0.12	1.28 ± 0.17	<b>1.16 ± 0.09</b>
Liver weight/Body weight (%)	4.24 ± 0.46	4.15 ± 0.43	4.27 ± 0.45	4.13 ± 0.37	4.01 ± 0.53	2.54 ± 0.19
Water intake (ml/kg bw/day)	122.9 ± 11.8	124.7 ± 9.8	120.1 ± 4.5	<b>113.7 ± 3.1</b>	113.1 ± 12.1	<b>97.7 ± 12.0</b>
Food Intake (kcal/kg bw/day)	485.9 ± 46.8	492.7 ± 38.7	474.7 ± 17.8	<b>449.2 ± 12.2</b>	447.1 ± 47.7	<b>386.2 ± 47.6</b>
Total Cholesterol (g/L)	0.63 ± 0.16	<b>0.48 ± 0.15</b>	0.57 ± 0.06	0.57 ± 0.08	0.54 ± 0.09	0.58 ± 0.10
Triglycerides (g/L)	0.42 ± 0.06	0.48 ± 0.17	0.66 ± 0.15	0.58 ± 0.12	0.39 ± 0.13	0.39 ± 0.08
NEFA (mmol/L)	0.44 ± 0.34	0.5 ± 0.39	0.49 ± 0.42	0.32 ± 0.29	0.27 ± 0.37	0.19 ± 0.23
Insuline (µg/ml)	0.94 ± 0.55	0.9 ± 0.67	1.23 ± 0.37	0.85 ± 0.69	0.67 ± 0.52	0.61 ± 0.20
Glucose (mg/dl)	164 ± 31.4	158.8 ± 37.7	147.3 ± 13.1	136.4 ± 22.63	151.5 ± 19.2	145.7 ± 22.2
Testosterone (pg/ml)	2 ± 1.2	1.4 ± 0.3	1.9 ± 0.3	<b>2.4 ± 0.52</b>	1.7 ± 0.41	1.9 ± 0.33

225

	F1 Female		F2 Female		F3 Female	
	CTRL	EPOX	CTRL	EPOX	CTRL	EPOX
Body Weight (g)	23.0 ± 1.4	22.6 ± 1.2	22.5 ± 1.0	22.5 ± 0.7	23.1 ± 1.2	22.7 ± 0.89
Fat mass (%)	14.4 ± 1.4	<b>13.1 ± 1.6</b>	13.5 ± 1.8	13.5 ± 2.9	12.3 ± 2.6	11.4 ± 1.6
Lean Mass (%)	74.7 ± 1.9	75.2 ± 0.8	77.1 ± 2.6	77.3 ± 3.1	76 ± 2.4	77.4 ± 1.8
Liver Weight (g)	0.83 ± 0.14	0.89 ± 0.09	0.84 ± 0.08	0.94 ± 0.07	0.99 ± 0.09	0.93 ± 0.08
Liver weight/Body weight (%)	3.59 ± 0.60	2.61 ± 0.32	3.77 ± 0.40	<b>4.18 ± 0.26</b>	4.28 ± 0.38	4.10 ± 0.33
Water intake (ml/kg bw/day)	181.5 ± 10.6	173.9 ± 13.6	125.5 ± 8.3	126.3 ± 10.5	122.3 ± 5.9	124.8 ± 4.1
Food Intake (kcal/kg bw/day)	142.3 ± 7.2	140.6 ± 13.1	496.0 ± 32.8	499.0 ± 41.6	483.5 ± 23.4	493.1 ± 16.4
Total Cholesterol (g/L)	0.32 ± 0.07	<b>0.45 ± 0.09</b>	0.40 ± 0.05	0.45 ± 0.11	0.5 ± 0.07	0.54 ± 0.06
Triglycerides (g/L)	0.28 ± 0.09	<b>0.47 ± 0.13</b>	0.29 ± 0.07	<b>0.37 ± 0.08</b>	0.4 ± 0.10	0.42 ± 0.06
NEFA (mmol/L)	0.31 ± 0.10	0.32 ± 0.29	0.15 ± 0.15	<b>0.4 ± 0.17</b>	0.23 ± 0.11	0.16 ± 0.04
Insuline (µg/ml)	0.69 ± 0.20	1.13 ± 0.80	1.09 ± 0.53	0.87 ± 0.29	0.52 ± 0.52	0.86 ± 0.66
Glucose (mg/dl)	139.6 ± 48.8	125.3 ± 46.5	114.7 ± 12.7	115.5 ± 17.4	135 ± 24.1	129.8 ± 19.9
Estradiol (pg/ml)	70.3 ± 13.7	<b>56.4 ± 15.9</b>	73.6 ± 11.2	77.1 ± 13.5	72.9 ± 11.1	76.9 ± 7.8

226 NEFA: No Esterified Fatty Acids; CTRL: control group; EPOX: epoxiconazole. Measurements were performed

227 at 23 week-old. Values represent means ± standard deviation (SD). Data in bold and italic are significant at p &lt;

228 0.05 with paired Student's t-test. n = 12/group

229

230 3.2. Multigenerational effects of epoxiconazole on hepatic metabolism:

231 **Effect of EPOX on liver weight** (Table 1): In males, no change in liver weight was232 observed whatever the generation between epoxiconazole *versus* control groups. Only in

233 female F2 mice, we observed a weak but significant increase of liver weight normalized to  
234 body weight (approximately 10%,  $p < 0.01$ ) in the EPOX group compared to the control group.

235 ***Histological liver analysis:*** We performed histological analysis of liver tissue by  
236 targeting the number of Kupffer macrophages cells, fibrosis, size of hepatocytes and their  
237 distribution according to their size in comparison with the control group. Our results showed  
238 that an exposure to EPOX did not induce any change in Kupffer cell count and liver fibrosis  
239 whatever the mouse sex and generation (supplementary data). In contrast, differences were  
240 observed in the average size of hepatocytes and/or their distribution according to their size. In  
241 male mice, an increase ( $p > 0.01$ ) in the average size of hepatocytes was observed in F1 (15%)  
242 and F3 (9%) mice associated with a tendency (no significant), to exhibit a proportion of larger  
243 hepatocytes (Figure 1). In females, hepatocyte size was also larger in F1 (11%;  $p < 0.01$ ) and  
244 was associated with a higher proportion of larger hepatocytes (47%;  $p < 0.01$ ). In contrast, in  
245 F3 mice, although there was no difference in the average hepatocyte size, there was a  
246 significant preponderance of small hepatocytes (27%;  $p < 0.05$ ). As for males, no significant  
247 difference was observed in F2 (Figure 2).

248

249


250

251

252


253

254



255 **Figure 1:** Transgenerational effects of epoxiconazole on the liver of male offspring  
 256 from EPOX-exposed F0 females (1.75 ug/kg/d): eosin/hematoxylin stainings in control mice  
 257 (CTRL; A - C) and epoxiconazole group (EPOX; D - F); distribution of hepatocytes  
 258 according to their size (EPOX vs CTRL; (G - I)); size of hepatocytes (J - L). Data are  
 259 expressed as the mean  $\pm$  SD. A Student's t-test or a Chi-square test has been achieved; \* p  
 260 <0.05; compared to controls for each generation. n = 12/group. Magnification x40.

261  
 262  
 263



264 **Figure 2:** Transgenerational effects of epoxiconazole on the liver of female offspring from  
 265 EPOX-exposed F0 females (1.75 ug/kg/d): eosin/hematoxylin stainings in control mice  
 266 (CTRL; A - C) and epoxiconazole group (EPOX; D - F); distribution of hepatocytes  
 267 according to their size (EPOX vs CTRL; (G - I)); size of hepatocytes (J - L),. Data are  
 268 expressed as the mean  $\pm$  SD. A Student's t-test or a Chi-square test has been achieved; \* p  
 269 <0.05; compared to controls for each generation. n = 12/group. Magnification x40.

270

271


272

273 3.3. Transcriptomic analysis in liver

274 To clarify the molecular mechanisms underlying and associated with the  
 275 transgenerational hepatic effects of EPOX, we performed a transcriptomic analysis. The  
 276 observed differential mRNA expressions were put in perspective of the associated biological  
 277 systems by an analysis with KEGG databases. To refine the analysis of the genes whose  
 278 expression is altered, comparisons between generations and between sexes of individuals  
 279 were performed.

### 280 3.3.1 Transgenerational effect of EPOX by gender and generation

281 Using a threshold of 1.5-fold and a p value <0.05, a significant number of genes among the  
 282 22,206 genes showed an alteration of their mRNA expression level with a preponderance of  
 283 down-regulated genes (supplementary data table S2 A, B and C for male mice and S2D, E and  
 284 F for female mice). A difference according to the sex was observed with a profile evolving  
 285 over the generations (Figure 3). F1 male mice were the most impacted with 1,903 deregulated  
 286 genes of which 1,177 (61.8%) were down-regulated. In females, F2 mice exhibited the most  
 287 altered transcriptomic profile with 891 deregulated genes of which 539 (60.5%) were down-



288 regulated.

289 Figure 3: Number of genes with mRNA expression significantly altered (at least 1.5-fold) in  
290 female and male mice of F1, F2 and F3 generations came from epoxiconazole-treated dams  
291 F0 in comparison with respective control group.

### 292 3.3.2 Functional gene set enrichment analysis (GSEA)

293 GSEA was performed with WebGestalt 2019 using the KEGG pathway databases.  
294 Biological systems associated with EPOX exposure also differed by sex and generation. In F1  
295 male mice, genes associated with increased ribosome activity, oxidative phosphorylation, and  
296 dysregulation leading to NAFLD were significantly represented (Figure 4 and Supplementary  
297 data table S1 for the list of concerned gene). Conversely, the systematic keywords, “circadian  
298 rhythm” and “metabolic pathway” emerged significantly down-regulated. Concerning F2  
299 males, two systems still appear significantly active ( $FDR < 0.05$ ), arachidonic acid metabolism  
300 and the PPARs signaling pathway while there is nothing statistically significant in F3.


301 In females, the olfactory transduction pathway appears to be activated in both F1 and  
302 F2, but the genes involved are not the same and are fewer in F2. In F3, only the PPARs  
303 signaling pathway is significantly ( $FDR < 0.05$ ) down-regulated (Figure 5 and Supplementary  
304 data table S1 for the list of concerned gene).

### 305 3.3.3 Comparison of transcriptomic profile over the generations and the gender

306 A comparative analysis of deregulated genes between generations was performed  
307 (Figure 6). The common differentially expressed genes among generations were then  
308 analyzed using String (<http://string-db.org/>). The analysis showed that in both males and  
309 females, the circadian rhythm is the system that is mainly altered. More specifically, in F1 and  
310 F2 males, there are also genes involved in energy metabolism that are deregulated, notably in  
311 the metabolism of glycerolipids, glycerophospholipids, insulin sensitivity and those  
312 associated with the development of type 2 diabetes. Differential mRNA expression of these  
313 genes is largely identical between F1 and F2 generations in males and females. In contrast,




314 genes common to the F2 and F3 generations showed a variation in mRNA expression in  
315 opposite directions (*e.g.*, the *ciart* gene is upregulated in F2 and downregulated in F3;  
316 supplementary data Table S2G for male mice and S2H for female mice).



317 Figure 4: Functional Gene Set Enrichment Analysis identified by the databases of pathways  
 318 KEGG for down- and up-regulated genes in the livers of male mice from epoxiconazole-


319 treated F0 dams in comparison with control mice for each generation. n = 3 pools of 3  
320 animals.



321 Figure 5: Functional Gene Set Enrichment Analysis identified by the databases of pathways  
 322 KEGG for down- and up-regulated genes in the livers of female mice from epoxiconazole-

323 treated F0 dams in comparison with control mice for each generation. n = 3 pools of 3  
 324 animals.

325 A comparison between generation of the altered genes (Figure 6 and Supplementary  
 326 Data S2I) indicates the same findings for females and males, namely an impact on circadian  
 327 rhythm and metabolic pathways. Interestingly, the mRNA expression profile of these common  
 328 genes is almost similar depending on the sex or generation considered.




329 Figure 6: Number of genes with altered mRNA expression and that are common across  
 330 generations and/or sex of the individual. In the yellow boxes, the values for females and in the  
 331 blue boxes, those for male mice. In the green boxes is indicated the number of genes common  
 332 between the two sexes and for each generation, respectively. Only five genes are common to  
 333 all generations and to both males and females.

334

335 Compiling all these data, the alteration of the expression of five genes appears to be  
 336 conserved over the generations independently of the individual sex: *Circadian Associated*  
 337 *Repressor of Transcription (Ciart)*, *Period Circadian Regulator 3 (Per3)*, *WEE 1 homolog 1*  
 338 *(Wee1)*, *Ubiquitin carboxyl-terminal hydrolase 2 (Usp2)* and *caseinolytic mitochondrial*  
 339 *matrix peptidase chaperone subunit (Clpx)*. Apart from this last gene, the other four are  
 340 associated with the control of the circadian rhythm (Figure 7).

341

342



343 Figure 7: String (string-db.org) analysis with the five genes commonly altered  
 344 whatever the sex and the generation of mice from EPOX-treated F0 dams in comparison with  
 345 control group.

#### 346 4. Discussion

##### 347 4.1 Originality and limitations of the study

##### 348 **Originality and contribution to the field:**

349 Studies investigating the hepatotoxicity of EPOX are obviously necessary and of great  
 350 interest, but they do not take into account two essential elements: the concept of low dose  
 351 exposure (closer to reality) and the developmental origins of health and disease (DOHAD).  
 352 This concept of DOHAD has greatly modified our understanding of what makes an individual  
 353 develop or not, in the course of his life, the main chronic diseases that affect rich or emerging  
 354 countries. It implies a shift in the paradigm on which prevention policies can be based on a  
 355 global scale, in the major field of epidemiology and mechanisms of non-communicable  
 356 diseases according to the World Health Organization classification (Desai et al., 2015). Thus,

357 based on a multigenerational study, our objective was to characterize the hepatotoxic effects  
358 of perinatal low-dose exposure of EPOX, particularly at the molecular level, and the  
359 consequences in the descendants.

### 360 *Limitations of the study*

361 The analysis of this type of study is complex because it incorporates several factors of  
362 physiological importance: the sex of the animal, the generation, the exposure, the dose and the  
363 substance studied. In order to characterize the effect of EPOX, the protocol was based on a  
364 previous laboratory study on another endocrine disruptor, bisphenol S (Brulport et al., 2021).  
365 This exposure protocol allows for the critical exposure windows of embryonic and fetal  
366 development and the lactation period. It also enables the study of transgenerational effects  
367 that may be observed in the third generation, which is the first generation not exposed to the  
368 substance, even indirectly *via* germ cells (as is the case for F2 generation).

369 The comparison with previous studies on the hepatotoxicity of EPOX is not very  
370 relevant because of the differences in the experimental strategy implemented in our study.  
371 Indeed, to date and to our knowledge, this is the first time that the transgenerational hepatic  
372 effects of EPOX, or even azole compounds, have been studied notably after gestational  
373 exposure.

374 The use of ethanol as vehicle for EPOX exposure may raise questions about these  
375 possible effects. Few studies have investigated the effect of ethanol exposure at low-dose  
376 during the gestation and lactation in laboratory mice, notably through drinking water. Allan *et*  
377 *al.* (2003) showed that maternal food consumption and care, and litter size and number were  
378 all found to be similar for the alcohol-exposed and control animals. Only an increase of the  
379 time spent inspecting a novel object introduced into the open field was observed. In their  
380 study, the average daily consumption of ethanol by mouse dams on the 10% ethanol solutions  
381 was 14.0 g ethanol/kg bw/d (about 7.2 mg ethanol/kg bw/d in our study). Without obscuring

382 the consequences of even small amounts of ethanol exposure, we also observed no significant  
383 differences in litter size or neonate weight (CTRL  $1.38 \pm 0.16$  g vs EPOX  $1.40 \pm 0.14$  g for  
384 F1; CTRL  $1.31 \pm 0.08$  g vs EPOX  $1.34 \pm 0.09$  g for F2; CTRL  $1.36 \pm 0.13$  g vs EPOX  $1.35 \pm$   
385  $0.11$  g for F3; values represent means  $\pm$  SD for neonates body weight at PND0). Similarly, the  
386 use of isoflurane to anaesthetize mice prior to euthanasia could potentially affect the  
387 expression of genes encoding cytochrome P450. Indeed, both ethanol and isoflurane have  
388 been described to induce CYP2A4 activity and mRNA expression (García-Suástegui et al.,  
389 2017). However, Plate *et al.* (2005) also reported that rats can be anaesthetized with isoflurane  
390 for a short period without a change in the activity of P450 enzymes (Plate et al., 2005). In  
391 order to avoid possible consequences, the time between the application of isoflurane and liver  
392 sampling was kept as short as possible.

#### 393 4.2 Physiological and histological consequences

394 Hamdi et al. (2019) described that EPOX induced significant histopathological  
395 changes (necrosis, dilatation and congestion of the central vein and portal triad, dilation of  
396 sinusoidal capillaries, lipid vacuolization, hemorrhage, and inflammatory leukocyte  
397 infiltration) in male Wistar rats exposed to 8, 24, 40 and 56 mg/kg bw/d for 28 days, with  
398 induction of oxidative stress associated with changes in liver biomarkers ALT, AST, ALP,  
399 LDH (Hamdi et al., 2019). In our study, changes in liver histology were also observed but we  
400 failed to identify transcriptomic changes indicating a link to oxidative stress. The oxidative  
401 activity of EPOX occurs mainly at high concentrations both *in vivo* and *in vitro* ( $10^{-5}$  M in  
402 human colon carcinoma cells (HCT116) for example (Hamdi et al., 2018)) which may explain  
403 its absence in our experimental conditions.

404 In male CD1 mice, Hester et al. reported that exposure for 30 days to EPOX doses  
405 ranging from 1 to 500  $\mu$ g/kg bw/d (carcinogenic doses) induced hepatic effects such as CYP  
406 induction, hepatic hypertrophy, hepatomegaly, increased cell proliferation, and decreased



407 serum cholesterol levels. Likewise, Heise *et al.* (2015, 2018) reported the effects of three  
408 widely used hepatotoxic (tri)azole fungicides (cyproconazole, epoxiconazole, and prochloraz)  
409 in a 28-day study in male rats. The three fungicides were administered individually or in  
410 mixture at doses ranging from 0.9 to 1000 µg/kg bw/d. Their results showed, at the highest  
411 dose, an increase in liver weight associated with histopathological changes, such as increased  
412 hepatocyte size and vacuolation (Heise et al., 2018, 2015). These results are quite similar to  
413 our results, except for the dose necessary to induce an observable effect. This difference is  
414 probably related to the gestational exposure in our study. These data underline the importance  
415 of the exposure window to harmful substances, especially during the critical phases of  
416 development.

417 In F3 males, although no biological system stands out significantly, the  
418 transgenerational consequence of EPOX exposure appears to be much more global as the F3  
419 male mice have a lower body weight than the control group, but no change in their body  
420 composition (lean and fat mass). These results suggest a smaller body size of these animals,  
421 which also associated with a decrease in food and water intake. The reasons for these  
422 physiological consequences are unclear and need to be further investigation.

#### 423 4.3 Key pathway associated with effect of EPOX: sex and generation dependent

424 To evaluate the consequences of the EPOX exposure in the liver, through mRNA  
425 expression, we set to a hypothesis-free approach. Ontological analysis allows to highlight the  
426 biological systems associated with the observed transcriptomic profile. In general, these  
427 perturbations are signs of a strongly impacted metabolic activity.

#### 428 *Hepatic metabolism*

429 Male F1 mice are the most affected by the hepatotoxic effect of EPOX with a  
430 stimulation of protein synthesis, oxidative phosphorylation and metabolic dysregulation  
431 associated with the development of NAFLD. This hepatic metabolic activity is confirmed by

432 the increase in hepatocyte size observed in these animals. Indeed, hepatocyte size is  
433 influenced by a number of factors such as regenerative activity and metabolic status. For  
434 example, the influx of solutes such as amino acids or glucose causes transmembrane  
435 movement of water into the cells, increasing their volume by 5-10% (Saxena, 2018).  
436 Increased glycogen or lipid stores may also impact on hepatocyte size. Although we did not  
437 measure hepatic triglycerides, an analysis of the rate of lipid infiltration (rough indicator) on  
438 liver HE/eosin sections by J-image showed no significant difference (data not shown).

#### 439 *Arachidonic acid pathway*

440 The arachidonic acid pathway appears to occur mainly in F2 male. It may indicate an  
441 inflammatory state that is not confirmed by histological analysis, particularly at the level of  
442 fibrosis.

#### 443 *Olfactory transduction*

444 Unexpectedly, in F1 and F2 female mice, GSEA showed an involvement of the gene  
445 encoded products in olfactory transduction with 31 olfactory receptor genes up-regulates. *Olf*  
446 genes are the largest gene superfamily in vertebrates with 1,296 mouse *Olf* genes (including  
447 20% pseudogenes) reported and classified into 228 families (Zhang and Firestein, 2002).  
448 Initially, these G protein-coupled receptors are described as recognizing and sensing volatile  
449 chemicals serving as exogenous ligands to mediate odor perception in the brain (Fleischer et  
450 al., 2009). These receptors are also ectopically expressed in other tissues such as testis, lung  
451 and liver, where they are also functional and activated by endogenous ligands (Kang and Koo,  
452 2012; Maßberg and Hatt, 2018). Even if the role of *Olf* receptors in the liver is not known  
453 yet, some recent studies have highlighted their involvement in hepatic energy metabolism. For  
454 example, olfactory receptor 544 (*Olf*544) is highly expressed in mouse liver and adipose  
455 tissue, where it has been implicated in the metabolic interaction between liver and adipose  
456 tissue. *Olf*544 leads to the mobilization of fat stored in the adipose tissue and the shift of

457 energy preference towards liver and brown adipose tissue (Wu et al., 2017). Likewise, in  
458 mouse livers and cultured mouse hepatocytes, Olfr43 activation was associated with a  
459 reduction in hepatic triglyceride accumulation in the mouse liver (Wu et al., 2019). Olfr  
460 receptors have also been described to be involved in glucose metabolism. For example, by  
461 using Olfr734 deficient mice, Li *et al.* (2019) reported that this receptor functioned as an  
462 Asprosin receptor to regulate hepatic glucose production. Asprosin is a fasting-induced  
463 hormone that stimulates glucose production in the liver and appetite at the hypothalamic level  
464 (Li et al., 2019). Although the biological significance of the GSEA results must be interpreted  
465 with caution, the regulation of 31 chemosensory receptor-encoding genes in mouse liver  
466 strongly suggests that EPOX has the potential to modulate the liver metabolism. Future  
467 studies are needed to clarify the biological consequences of the regulation of a large number  
468 of chemosensory receptor genes in the liver.

#### 469 ***PPAR $\alpha$ pathway***

470 In F3 females, olfactory transduction still appears in the GSEA, but not significantly  
471 (FDR>0.05). In contrast, some genes associated with the PPAR signaling pathway were  
472 downregulated. PPAR $\alpha$  regulates lipid metabolism in the liver as a major control of fatty acid  
473 oxidation and energy generation in a fasted state (Wang et al., 2020). Decreased stimulation of  
474 the PPAR $\alpha$  signaling pathway may thus be associated with hepatocytes exhibiting less  
475 metabolic activity, which correlates with the higher proportion of smaller hepatocytes  
476 observed in the present study. However, it is also noteworthy that some genes for ribosomal  
477 and oxidative phosphorylation processes tend to be upregulated, but in a non-significant  
478 manner (FDR>0.05). A stimulation of protein synthesis and oxidative phosphorylation can  
479 therefore not be excluded. This can be explained by the cellular specificity of PPAR $\alpha$   
480 activities and the diversity of hepatic cells. The liver is composed of 80% hepatocytes and  
481 20% non-parenchymal cells (Kupffer cells, hepatic sinusoidal endothelial cells and hepatic

482 stellate cells) involved in intercellular trafficking and immune regulation (Werner et al.,  
483 2015). Thus, each cell type may respond differently to EPOX exposure. Indeed, it is unclear  
484 which hepatic cell type is principally involved in PPAR $\alpha$  function in lipid homeostasis and  
485 phenotypes such as hepatomegaly and hepatocyte proliferation. For example, cell  
486 proliferation has been described as mediated exclusively by PPAR $\alpha$  activation in hepatocytes,  
487 whereas Kupffer cell PPAR $\alpha$  has an important role in the mediation of anti-inflammatory  
488 effects of PPAR $\alpha$  agonists (Brocker et al., 2017).

489         Activation of the PPAR pathway may also be an indicator of inflammation. In  
490 accordance with these data, in these male F2 mice, we observed an enhancement of mRNA  
491 expression for *Cyp4a31* (1.94-fold), *Cyp4a32* (2.21-fold) and *Cyp4a14* (11,91-fold). The  
492 significant increase of *CYP4a* gene expression is associated with PPAR-dependent liver  
493 inflammation. (Mitchell et al., 2001). Members of the CYP4A subfamily catalyze the  
494 hydroxylation of fatty acids such as arachidonic acid (Nguyen et al., 1999) and Sharma *et al.*  
495 demonstrated that their expression in rodent livers is induced by PPAR nuclear receptors  
496 (Sharma et al., 1989). Interestingly, a characteristic of hepatic CYP4A induction by PPAR in  
497 this species is a marked sex difference, females being refractory (Sundseth and Waxman,  
498 1992).

499

#### 500         4.4 Transcriptomic transgenerational effect of EPOX

501         Mutual genes in males and females showed similar expression variations between F1  
502 and F2 and complete opposition between F2 and F3. It seems that molecular mechanisms are  
503 set up during the generations to counterbalance the effects of EPOX exposure in F0 pregnant  
504 females. In this study, these variations in gene expression observed in F3 are still associated  
505 with physiological disorders either at the individual level (e.g. body weight of F3 males) or at  
506 the histological and transcriptomic levels (F3 females). Taken together, these data indicate

507 that EPOX induces a transgenerational effect in a sex-dependent manner. Many mechanisms  
508 by which exposure to harmful substances could lead to liver disease have been identified  
509 (Foulds et al., 2017). For example, correlations between endocrine disruptor exposures during  
510 the development and changes in gene expression are associated with DNA methylation,  
511 histone code pattern variations, or interference with microRNAs (Barouki et al., 2018).

#### 512 4.4 The circadian rhythm: a key factor of the EPOX effect across generations?

513 Comparison of genes between males and females in each generation indicates that  
514 some genes are similarly altered in all generations. Surprisingly, these genes are involved in  
515 controlling the circadian rhythm of gene expression. As described in the results section, the  
516 five genes *Ciart*, *Wee1*, *Per3*, *Clpx*, and *Usp2* are the only ones that have their expression  
517 altered regardless of sex or generation.

518 The circadian clock system includes the central clock in the suprachiasmatic nucleus  
519 of the hypothalamus and peripheral clocks located in peripheral tissues. At the hepatic level,  
520 they are involved in the hepatic homeostasis by playing an important role in the regulation of  
521 energy metabolism and the expression of enzymes regulating the absorption and metabolism  
522 of xenobiotics. Dysregulation of the liver clock is involved in the development of liver  
523 diseases such as fatty liver disease, cirrhosis, hepatitis and liver cancer, and these disorders  
524 also disrupt the function of the liver clock (Tahara and Shibata, 2016).

525 Many genes related to liver metabolism (lipogenesis, gluconeogenesis, mitochondrial  
526 activity, bile acid synthesis and oxidative metabolism) show circadian variation in their  
527 expression (Bass and Takahashi, 2010). In mice, alteration of the core clock genes results in  
528 metabolic disorders. Interestingly, mice with a *Clock* gene mutation (*Clock $\Delta$ 19/ $\Delta$ 19*) had a  
529 decrease of insulin plasma level and an increase of cholesterol and triglyceride plasma levels  
530 in comparison with wild-type mice (Marcheva et al., 2010). In concordance with our results  
531 showing the involvement of PPAR pathway, it was reported that PPAR nuclear receptors are

532 important regulators of the circadian clock system and subsequently of energy metabolism  
533 (Schmutz et al., 2010; Tahara and Shibata, 2016). Likewise, many CYP phase I superfamily  
534 mRNAs, including Cyp4a14, are expressed rhythmically in mice, with enhanced levels during  
535 the dark phase (Zhang et al., 2009). Thus, the sex and generation-dependent disturbances  
536 appear to be inseparable from a deregulation of the circadian rhythm, which is sex and  
537 generation-independent. At this stage, it is obviously impossible to determine the causal link  
538 of these mechanisms.

### 539 *EPOX induce a gender-dependent transgenerational effect*

540 From a physiological and transcriptomic point of view, EPOX induce sex-dependent  
541 effects in mice. This discordance suggests sex hormone-dependent effects potentially related  
542 to the estrogenic and anti-androgenic properties of EPOX, both in the activity and synthesis of  
543 these hormones (DAR, 2006). In agreement with these data, in our study, EPOX induced a  
544 decrease in plasma estradiol levels in F1 females, which has been previously reported in GD  
545 21 Wistar dams, but exposed to a high dose of EPOX (50 mg/kg/bw) (Taxvig et al., 2008).  
546 Decreased estrogen levels are classically associated with increased body fat (Mauvais-Jarvis  
547 et al., 2013), which is the opposite in the present study. These results therefore suggest that  
548 other mechanisms may be involved, particularly at the level of adipose tissue. Indeed, as  
549 indicated by the increase in plasma triglyceride levels, the lipolytic activity and/or the uptake  
550 of triglycerides by adipose tissue could be impacted (Beigneux et al., 2007; Hajer et al.,  
551 2008).

552 These sex-dependent effects could also result, in part, from a different toxicokinetic of  
553 EPOX between males and females. The metabolism of EPOX is rapid and extensive with the  
554 production of at least 47 metabolites in rat. However, its elimination is slow and no major  
555 differences in the metabolism of epoxiconazole in rats were observed with regard to sex and  
556 dose level. However, based on urinary and biliary elimination, oral bioavailability was

557 approximately 80% in males and 50% in females (DAR, 2006). This concept would only  
558 concern mice of the F1 generation, which is the only one potentially exposed during the  
559 lactation.

560

## 561 **5. Conclusion**

562 Hepatotoxicity of epoxiconazole has been shown following high dose exposure in adult  
563 rodent. In this study, we demonstrate that this fungicide is able to induce hepatic perturbations  
564 in mice following a low dose perinatal exposure. These effects also show a transgenerational  
565 pattern with strong disparities according to the sex and generation of the animals. This study  
566 also highlights the potential involvement of a disruption of the hepatic circadian rhythm. The  
567 data obtained indicate a likely alteration of the inflammatory status of the liver, but with no  
568 observable histological consequences at the age of the animals in this study. As a consequence  
569 of these effects at the transcriptional level, the question of the long-term development of more  
570 severe liver pathologies (NASH, NAFLD, cirrhosis, cancer) remains to be studied.

## 571 **6. Declaration of competing interest.**

572 The authors declare that they have no known competing financial interests or personal  
573 relationships that could have appeared to influence the work reported in this paper.

## 574 **7. Acknowledgments**

575 This work was financed by a grant from the National Research Program Ecophyto II  
576 and Endocrine Disruptors supported by the "Ministère de l'Agriculture et de l'Alimentation"  
577 and the "Ministère de la Transition Ecologique et Solidaire". This work was also funded by  
578 Ministère de l'Enseignement Supérieur et de la Recherche (doctoral fellowship to AB). We  
579 thank the zootechnical platform of the University of Burgundy for its technical assistance.

580

581 **8. References**

- 582 Bass, J., Takahashi, J.S., 2010. Circadian integration of metabolism and energetics. *Science*  
583 330, 1349–1354. <https://doi.org/10.1126/science.1195027>
- 584 Beigneux, A.P., Davies, B.S., Gin, P., Weinstein, M.M., Farber, E., Qiao, X., Peale, F.,  
585 Bunting, S., Walzem, R.L., Wong, J.S., Blaner, W.S., Ding, Z.M., Melford, K., Wongsiriroj,  
586 N., Shu, X., de Sauvage, F., Ryan, R.O., Fong, L.G., Bensadoun, A., Young, S.G., 2007.  
587 Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a  
588 critical role in the lipolytic processing of chylomicrons. *Cell Metab* 5, 279–91.  
589 [https://doi.org/S1550-4131\(07\)00034-4](https://doi.org/S1550-4131(07)00034-4) [pii] 10.1016/j.cmet.2007.02.002
- 590 Brulport, A., Le Corre, L., Maquart, G., Barbet, V., Dastugue, A., Severin, I., Vaiman, D.,  
591 Chagnon, M.-C., 2021. Multigenerational study of the obesogen effects of bisphenol S after a  
592 perinatal exposure in C57BL6/J mice fed a high fat diet. *Environ Pollut* 270, 116243.  
593 <https://doi.org/10.1016/j.envpol.2020.116243>
- 594 Curley, J.P., Mashoodh, R., Champagne, F.A., 2011. Epigenetics and the origins of paternal  
595 effects. *Horm Behav* 59, 306–314. <https://doi.org/10.1016/j.yhbeh.2010.06.018>
- 596 DAR, 2006. Draft Assessment Report (DAR), public version. In: R. M. S. GERMANY,  
597 editor. Annex B, B.1-B7.
- 598 Desai, M., Jellyman, J.K., Ross, M.G., 2015. Epigenomics, gestational programming and risk  
599 of metabolic syndrome. *Int J Obes (Lond)*. <https://doi.org/10.1038/ijo.2015.13> ijo201513 [pii]
- 600 Diamanti-Kandarakis, E., Bourguignon, J.-P., Giudice, L.C., Hauser, R., Prins, G.S., Soto,  
601 A.M., Zoeller, R.T., Gore, A.C., 2009. Endocrine-disrupting chemicals: an Endocrine Society  
602 scientific statement. *Endocr. Rev.* 30, 293–342. <https://doi.org/10.1210/er.2009-0002>



603 Dunn, G.A., Morgan, C.P., Bale, T.L., 2011. Sex-specificity in transgenerational epigenetic  
604 programming. *Horm Behav* 59, 290–295. <https://doi.org/10.1016/j.yhbeh.2010.05.004>

605 Fleischer, J., Breer, H., Strotmann, J., 2009. Mammalian olfactory receptors. *Front Cell*  
606 *Neurosci* 3, 9. <https://doi.org/10.3389/neuro.03.009.2009>

607 García-Suástegui, W.A., Ramos-Chávez, L.A., Rubio-Osornio, M., Calvillo-Velasco, M.,  
608 Atzin-Méndez, J.A., Guevara, J., Silva-Adaya, D., 2017. The Role of CYP2E1 in the Drug  
609 Metabolism or Bioactivation in the Brain. *Oxid Med Cell Longev* 2017, 4680732.  
610 <https://doi.org/10.1155/2017/4680732>

611 Goetz, A.K., Ren, H., Schmid, J.E., Blystone, C.R., Thillainadarajah, I., Best, D.S., Nichols,  
612 H.P., Strader, L.F., Wolf, D.C., Narotsky, M.G., Rockett, J.C., Dix, D.J., 2007. Disruption of  
613 testosterone homeostasis as a mode of action for the reproductive toxicity of triazole  
614 fungicides in the male rat. *Toxicol Sci* 95, 227–39. <https://doi.org/kfl124> [pii]  
615 10.1093/toxsci/kfl124

616 Gore, A.C., 2015. Prenatal Programming and Endocrinology. *Endocrinology* 156, 3403–3404.  
617 <https://doi.org/10.1210/en.2015-1671>

618 Hajer, G.R., van Haefen, T.W., Visseren, F.L., 2008. Adipose tissue dysfunction in obesity,  
619 diabetes, and vascular diseases. *Eur Heart J* 29, 2959–71.  
620 <https://doi.org/10.1093/eurheartj/ehn387> ehn387 [pii]

621 Hamdi, H., Ben Salem, I., Ben Othmène, Y., Annabi, E., Abid-Essefi, S., 2018. The  
622 involvement of ROS generation on Epoxiconazole-induced toxicity in HCT116 cells.  
623 *Pesticide Biochemistry and Physiology* 148, 62–67.  
624 <https://doi.org/10.1016/j.pestbp.2018.03.014>

625 Hamdi, H., Othmène, Y.B., Ammar, O., Klifi, A., Hallara, E., Ghali, F.B., Houas, Z., Najjar,  
626 M.F., Abid-Essefi, S., 2019. Oxidative stress, genotoxicity, biochemical and histopathological  
627 modifications induced by epoxiconazole in liver and kidney of Wistar rats. *Environ Sci Pollut*  
628 *Res Int* 26, 17535–17547. <https://doi.org/10.1007/s11356-019-05022-3>

629 Heise, T., Schmidt, F., Knebel, C., Rieke, S., Haider, W., Geburek, I., Niemann, L., Marx-  
630 Stoelting, P., 2018. Hepatotoxic combination effects of three azole fungicides in a broad dose  
631 range. *Arch Toxicol* 92, 859–872. <https://doi.org/10.1007/s00204-017-2087-6>

632 Heise, T., Schmidt, F., Knebel, C., Rieke, S., Haider, W., Pfeil, R., Kneuer, C., Niemann, L.,  
633 Marx-Stoelting, P., 2015. Hepatotoxic effects of (tri)azole fungicides in a broad dose range.  
634 *Arch Toxicol* 89, 2105–2117. <https://doi.org/10.1007/s00204-014-1336-1>

635 Hester, S., Moore, T., Padgett, W.T., Murphy, L., Wood, C.E., Nesnow, S., 2012. The  
636 hepatocarcinogenic conazoles: cyproconazole, epoxiconazole, and propiconazole induce a  
637 common set of toxicological and transcriptional responses. *Toxicol Sci* 127, 54–65.  
638 <https://doi.org/10.1093/toxsci/kfs086>

639 Kang, N., Koo, J., 2012. Olfactory receptors in non-chemosensory tissues. *BMB Rep* 45,  
640 612–622. <https://doi.org/10.5483/bmbrep.2012.45.11.232>

641 Lepesheva, G.I., Hargrove, T.Y., Kleshchenko, Y., Nes, W.D., Villalta, F., Waterman, M.R.,  
642 2008. CYP51: A major drug target in the cytochrome P450 superfamily. *Lipids* 43, 1117–25.  
643 <https://doi.org/10.1007/s11745-008-3225-y>

644 Li, E., Shan, H., Chen, L., Long, A., Zhang, Y., Liu, Y., Jia, L., Wei, F., Han, J., Li, T., Liu,  
645 X., Deng, H., Wang, Y., 2019. OLF734 Mediates Glucose Metabolism as a Receptor of  
646 Asprosin. *Cell Metab* 30, 319-328.e8. <https://doi.org/10.1016/j.cmet.2019.05.022>

647 Marcheva, B., Ramsey, K.M., Buhr, E.D., Kobayashi, Y., Su, H., Ko, C.H., Ivanova, G.,  
648 Omura, C., Mo, S., Vitaterna, M.H., Lopez, J.P., Philipson, L.H., Bradfield, C.A., Crosby,  
649 S.D., JeBailey, L., Wang, X., Takahashi, J.S., Bass, J., 2010. Disruption of the clock  
650 components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. *Nature* 466, 627–  
651 631. <https://doi.org/10.1038/nature09253>

652 Maßberg, D., Hatt, H., 2018. Human Olfactory Receptors: Novel Cellular Functions Outside  
653 of the Nose. *Physiological Reviews* 98, 1739–1763.  
654 <https://doi.org/10.1152/physrev.00013.2017>

655 Mauvais-Jarvis, F., Clegg, D.J., Hevener, A.L., 2013. The role of estrogens in control of  
656 energy balance and glucose homeostasis. *Endocr Rev* 34, 309–38.  
657 <https://doi.org/10.1210/er.2012-1055> er.2012-1055 [pii]

658 Mitchell, S.R., Sewer, M.B., Kardar, S.S., Morgan, E.T., 2001. Characterization of Cyp4a  
659 Induction in Rat Liver by Inflammatory Stimuli: Dependence on Sex, Strain, and  
660 Inflammation-Evoked Hypophagia. *Drug Metab Dispos* 29, 17–22.

661 Nguyen, X., Wang, M.H., Reddy, K.M., Falck, J.R., Schwartzman, M.L., 1999. Kinetic  
662 profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific  
663 inhibitors. *Am J Physiol* 276, R1691-1700. <https://doi.org/10.1152/ajpregu.1999.276.6.R1691>

664 Plate, A.Y.A., Crankshaw, D.L., Gallaher, D.D., 2005. The effect of anesthesia by diethyl  
665 ether or isoflurane on activity of cytochrome P450 2E1 and P450 reductases in rat liver.  
666 *Anesth Analg* 101, 1063–1064. <https://doi.org/10.1213/01.ane.0000166791.30963.ef>

667 Saxena, R., 2018. 1 - Microscopic Anatomy, Basic Terms, and Elemental Lesions, in: Saxena,  
668 R. (Ed.), *Practical Hepatic Pathology: A Diagnostic Approach (Second Edition)*, Pattern

669 Recognition. Elsevier, Philadelphia, pp. 3–29. [https://doi.org/10.1016/B978-0-323-42873-](https://doi.org/10.1016/B978-0-323-42873-6.00001-9)  
670 6.00001-9

671 Schmutz, I., Ripperger, J.A., Baeriswyl-Aebischer, S., Albrecht, U., 2010. The mammalian  
672 clock component PERIOD2 coordinates circadian output by interaction with nuclear  
673 receptors. *Genes Dev* 24, 345–357. <https://doi.org/10.1101/gad.564110>

674 Sharma, R.K., Lake, B.G., Makowski, R., Bradshaw, T., Earnshaw, D., Dale, J.W., Gibson,  
675 G.G., 1989. Differential induction of peroxisomal and microsomal fatty-acid-oxidising  
676 enzymes by peroxisome proliferators in rat liver and kidney. Characterisation of a renal  
677 cytochrome P-450 and implications for peroxisome proliferation. *Eur J Biochem* 184, 69–78.  
678 <https://doi.org/10.1111/j.1432-1033.1989.tb14991.x>

679 Sugathan, A., Waxman, D.J., 2013. Genome-wide analysis of chromatin states reveals distinct  
680 mechanisms of sex-dependent gene regulation in male and female mouse liver. *Mol. Cell.*  
681 *Biol.* 33, 3594–3610. <https://doi.org/10.1128/MCB.00280-13>

682 Sundseth, S.S., Waxman, D.J., 1992. Sex-dependent expression and clofibrate inducibility of  
683 cytochrome P450 4A fatty acid omega-hydroxylases. Male specificity of liver and kidney  
684 CYP4A2 mRNA and tissue-specific regulation by growth hormone and testosterone. *J Biol*  
685 *Chem* 267, 3915–3921.

686 Tahara, Y., Shibata, S., 2016. Circadian rhythms of liver physiology and disease:  
687 experimental and clinical evidence. *Nat Rev Gastroenterol Hepatol* 13, 217–226.  
688 <https://doi.org/10.1038/nrgastro.2016.8>

689 Taxvig, C., Vinggaard, A.M., Hass, U., Axelstad, M., Metzdorff, S., Nellemann, C., 2008.  
690 Endocrine-disrupting properties in vivo of widely used azole fungicides. *Int J Androl* 31, 170–  
691 7. <https://doi.org/IJA838> [pii] 10.1111/j.1365-2605.2007.00838.x

692 Trasande, L., Zoeller, R.T., Hass, U., Kortenkamp, A., Grandjean, P., Myers, J.P., DiGangi,  
693 J., Bellanger, M., Hauser, R., Legler, J., Skakkebaek, N.E., Heindel, J.J., 2015. Estimating  
694 burden and disease costs of exposure to endocrine-disrupting chemicals in the European  
695 union. *J Clin Endocrinol Metab* 100, 1245–55. <https://doi.org/10.1210/jc.2014-4324>

696 Vinggaard, A.M., Joergensen, E.C., Larsen, J.C., 1999. Rapid and sensitive reporter gene  
697 assays for detection of antiandrogenic and estrogenic effects of environmental chemicals.  
698 *Toxicol Appl Pharmacol* 155, 150–60. <https://doi.org/S0041008X98985982> [pii]

699 Wang, Y., Nakajima, T., Gonzalez, F.J., Tanaka, N., 2020. PPARs as Metabolic Regulators in  
700 the Liver: Lessons from Liver-Specific PPAR-Null Mice. *Int J Mol Sci* 21, E2061.  
701 <https://doi.org/10.3390/ijms21062061>

702 Werner, M., Driftmann, S., Kleinehr, K., Kaiser, G.M., Mathé, Z., Treckmann, J.-W., Paul,  
703 A., Skibbe, K., Timm, J., Canbay, A., Gerken, G., Schlaak, J.F., Broering, R., 2015. All-In-  
704 One: Advanced preparation of Human Parenchymal and Non-Parenchymal Liver Cells. *PLoS*  
705 *One* 10, e0138655. <https://doi.org/10.1371/journal.pone.0138655>

706 Wu, C., Hwang, S.H., Jia, Y., Choi, J., Kim, Y.-J., Choi, D., Pathiraja, D., Choi, I.-G., Koo,  
707 S.-H., Lee, S.-J., 2017. Olfactory receptor 544 reduces adiposity by steering fuel preference  
708 toward fats. *J Clin Invest* 127, 4118–4123. <https://doi.org/10.1172/JCI89344>

709 Wu, C., Thach, T.T., Kim, Y.-J., Lee, S.-J., 2019. Olfactory receptor 43 reduces hepatic lipid  
710 accumulation and adiposity in mice. *Biochim Biophys Acta Mol Cell Biol Lipids* 1864, 489–  
711 499. <https://doi.org/10.1016/j.bbalip.2019.01.004>

712 Wuttke, W., Pitzel, L., Seidlova-Wuttke, D., Hinney, B., 2001. LH pulses and the corpus  
713 luteum: the luteal phase deficiency LPD). *Vitam Horm* 63, 131–58.

714 Zhang, X., Firestein, S., 2002. The olfactory receptor gene superfamily of the mouse. *Nat*  
715 *Neurosci* 5, 124–133. <https://doi.org/10.1038/nm800>

716 Zhang, Y.-K.J., Yeager, R.L., Klaassen, C.D., 2009. Circadian expression profiles of drug-  
717 processing genes and transcription factors in mouse liver. *Drug Metab Dispos* 37, 106–115.  
718 <https://doi.org/10.1124/dmd.108.024174>

719

